BDX
$180.67+2.19%
as of close, Oct 5, 2026
☾ AH $180.67 +2.19%
Becton Dickinson and CompanyStock · HealthcareS&P 500 Equal Weight 0.2%S&P 500 0.06%Russell 1000 0.06%Russell 3000 0.06%US Stock Market 0.06%MSCI ACWI 0.05%MSCI World 0.05%
BDX — Becton Dickinson and Company price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDED
120.0130.0140.0150.0160.0170.0180.0190.0200.0210.0220.0020.0M$180.67—20162019202120242026
2026-10-05
Price$180.67
MA20$163.44
MA50$158.07
Vol6.6M
Key stats#
Price data
- Price
- $180.67
- YTD price return
- +18.42%
- YTD total return
- +20.72%
- Next earnings
- Nov 5, 2026
- Market cap
- 49.2B
- Enterprise value
- 66.2B
- Shares outstanding
- 272.4M
- 52W low
- $127.59
- 52W high
- $193.07
- From 52W high
- -6.42%
- From 52W low
- +41.61%
- 52W range
- 81%
- Beta
- 0.20
Volume
- Rel volume
- 0.94×
- 30D volume
- 1.7M
- 30D $ vol
- 318.1M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$14K
- Insider net 3M
- −$1.3M
- Insider net 1Y
- −$2.6M
Form 4 transactions by trade date, as filed; latest on file 2026-09-28.
Fundamentals
- Sales (ttm)
- 23.3B
- Sales/share
- $85.36
- EPS (ttm)
- $3.33
- FCF (ttm)
- 3.2B
- FCF/share
- $11.76
- Book value/share
- $89.64
- Net margin
- 4.05%
- ROE
- 3.85%
- ROA
- 1.85%
- Debt / equity
- 0.55×
- Current ratio
- 0.87
Growth (CAGR, ttm) · 10Y
- Sales
- +17.37%+6.87%+3.46%+6.57%
- Net income
- -40.65%-17.30%-13.61%-1.88%
- FCF
- +54.26%+22.48%-5.56%+5.26%
- Shares
- -4.97%-2.08%-1.05%+2.49%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -39.22%-16.90%-12.16%-4.46%
- Sales/share
- +23.51%+9.14%+4.56%+3.97%
- FCF/share
- +62.33%+25.08%-4.55%+2.70%
- Book value/share
- +0.87%+0.09%+1.30%+9.04%
- Dividend/share
- +9.48%+6.13%+5.65%+5.79%
- Price
- +19.77%-4.16%-0.63%+2.95%
- Total return
- +22.96%-1.79%+1.56%+4.98%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 54.2×
- P/OI (ttm)
- 19.8×
- Fwd P/E
- 13.3×
- P/S (ttm)
- 2.1×
- P/B (mrq)
- 2.0×
- P/FCF (ttm)
- 15.4×
- EV/EBITDA (fy)
- 13.3×
- EV/Sales (ttm)
- 2.8×
- FCF yield (ttm)
- 6.51%
- Dividend yield (fwd)
- 2.32%
- Dividend yield (ttm)
- 2.32%
- Dividend/share (fwd)
- $4.20
- Buyback yield (realized, 1y)
- 4.97%
- Shareholder yield (realized, 1y)
- 8.05%
- Buyback yield (cash, ttm)
- 5.08%
- Shareholder yield (cash, ttm)
- 7.51%
Vs own 10Y history
- P/E
- 79th
- P/OI
- 20th
- P/S
- 11th
- P/B
- 19th
- P/FCF
- 13th
Bar = where today’s multiple sits in BDX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-05#
1D
+2.19%
5D
-1.72%
1M
-2.20%
3M
+14.29%
YTD
+18.42%
1Y
+18.70%
5Y
-3.09%
Recent filings#
- Sep 28Insider sale · Feld Michael (EVP, Chief Revenue Officer) sold 76 shares for $14K at $183.70 under a 10b5-1 plan
- Aug 26Insider sale · Feld Michael (EVP, Chief Revenue Officer) sold 165 shares for $31K at $188.49 under a 10b5-1 plan
- Aug 13Insider sale · Polen Thomas E Jr (Chairman, CEO and President · Director) sold 4,152 shares for $768K at $185.00 under a 10b5-1 plan
- Aug 11Insider sale · Goette Roland (EVP and President, EMEA) sold 2,438 shares for $441K at $180.84
- Aug 6Earnings · Earnings release — EPS $3.23 vs $3.14 est. (+2.9%); revenue $4.98B (+5% y/y) 3.8%
Financial statements
Open full BDX financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | -0.54% | +0.02% |
| JNJ | Johnson & Johnson | -8.10% | -1.21% |
| ABBV | AbbVie Inc. | +3.63% | +1.12% |
| MRK | Merck & Co. Inc. | -7.18% | -3.30% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -4.67% | +1.80% |
| TMO | Thermo Fisher Scientific Inc. | +10.26% | +3.35% |
| AMGN | Amgen Inc. | -7.83% | -0.01% |
| GILD | Gilead Sciences Inc. | -4.22% | -0.08% |
